{"organizations": [], "uuid": "8d1aed8d21710bc53c03a2482e9a676f9be1dbf0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-prometic-announces-realignment-of/brief-prometic-announces-realignment-of-its-clinical-program-priorities-for-2018-idUSFWN1QA13F", "country": "US", "domain_rank": 408, "title": "BRIEF-Prometic Announces Realignment Of Its Clinical Program Priorities For 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T01:22:00.000+02:00", "replies_count": 0, "uuid": "8d1aed8d21710bc53c03a2482e9a676f9be1dbf0"}, "author": "", "url": "https://www.reuters.com/article/brief-prometic-announces-realignment-of/brief-prometic-announces-realignment-of-its-clinical-program-priorities-for-2018-idUSFWN1QA13F", "ord_in_thread": 0, "title": "BRIEF-Prometic Announces Realignment Of Its Clinical Program Priorities For 2018", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "prometic life sciences inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC ANNOUNCES REALIGNMENT OF ITS CLINICAL PROGRAM PRIORITIES FOR 2018\n* PROMETIC LIFE SCIENCES - AS PART OF REALIGNMENT, CO TERMINATED PBI-4050 CLINICAL TRIAL IN CYSTIC FIBROSIS RELATED DIABETES\n* PROMETIC LIFE SCIENCES INC - AS PART OF REALIGNMENT, CO IS EVALUATING NEED TO CONTINUE OTHER ON-GOING CLINICAL PROGRAMS WITH PBI-4050\n* PROMETIC LIFE SCIENCES-EVALUATING CLINICAL DEVELOPMENT STRATEGY REGARDING FOLLOW-ON COMPOUNDS WHICH SHARE SAME UNIQUE MECHANISM OF ACTION WITH PBI-4050 Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-21T01:22:00.000+02:00", "crawled": "2018-02-21T01:35:44.012+02:00", "highlightTitle": ""}